Savara says Europe, Australia grant MOLBREEVI liquid formulation patents through 2041
Reuters2026/07/30 12:11- Savara secured granted patents in Europe and Australia covering the liquid formulation of MOLBREEVI, extending protection through March 2041.
- The Europe grant is European patent No. 4121000; the Australia grant is patent No. 62/990,810.
- The announcement strengthens intellectual property coverage for MOLBREEVI outside the US as Savara advances related US filings.
- Savara cited a separate joint European patent with PARI for a MOLBREEVI drug-device combination, running through March 2043.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Circle obtains Major Payment Institution license in Singapore
Crypto prices
More
